797 related articles for article (PubMed ID: 22943064)
41. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease.
Voskaridou E; Douskou M; Terpos E; Papassotiriou I; Stamoulakatou A; Ourailidis A; Loutradi A; Loukopoulos D
Br J Haematol; 2004 Sep; 126(5):736-42. PubMed ID: 15327528
[TBL] [Abstract][Full Text] [Related]
42. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
[TBL] [Abstract][Full Text] [Related]
43. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment.
Chirico V; Rigoli L; Lacquaniti A; Salpietro V; Piraino B; Amorini M; Salpietro C; Arrigo T
Eur J Haematol; 2015 May; 94(5):404-12. PubMed ID: 25200112
[TBL] [Abstract][Full Text] [Related]
44. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
Voskaridou E; Komninaka V; Karavas A; Terpos E; Akianidis V; Christoulas D
Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310
[TBL] [Abstract][Full Text] [Related]
45. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2* magnetic resonance imaging.
Wahidiyat PA; Liauw F; Sekarsari D; Putriasih SA; Berdoukas V; Pennell DJ
Hematology; 2017 Sep; 22(8):501-507. PubMed ID: 28218005
[TBL] [Abstract][Full Text] [Related]
47. [Liver and heart iron deposition status in patients with β thalassemia major: a multicenter study].
Li C; Liu S; Wang Y; Wen F; Gao H; Chen G; Li C; Wu X; Fang J; Hao W; Liu R; Zhang X; Chu CW; Au W
Zhonghua Er Ke Za Zhi; 2014 Feb; 52(2):90-3. PubMed ID: 24739717
[TBL] [Abstract][Full Text] [Related]
48. Iron distribution and histopathological characterization of the liver and heart of β-thalassemic mice with parenteral iron overload: Effects of deferoxamine and deferiprone.
Yatmark P; Morales NP; Chaisri U; Wichaiyo S; Hemstapat W; Srichairatanakool S; Svasti S; Fucharoen S
Exp Toxicol Pathol; 2014 Sep; 66(7):333-43. PubMed ID: 24907196
[TBL] [Abstract][Full Text] [Related]
49. Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.
Karakukcu C; Karakukcu M; Unal E; Patiroglu T; Ozdemir MA; Torun YA; Tang PH
Hemoglobin; 2012; 36(3):219-29. PubMed ID: 22483337
[TBL] [Abstract][Full Text] [Related]
50. T2* magnetic resonance and myocardial iron in thalassemia.
Pennell DJ
Ann N Y Acad Sci; 2005; 1054():373-8. PubMed ID: 16339685
[TBL] [Abstract][Full Text] [Related]
51. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
[TBL] [Abstract][Full Text] [Related]
52. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
Peng CT; Tsai CH; Wu KH
Hemoglobin; 2008; 32(1-2):49-62. PubMed ID: 18274983
[TBL] [Abstract][Full Text] [Related]
53. A T2* magnetic resonance imaging study of pancreatic iron overload in thalassemia major.
Au WY; Lam WW; Chu W; Tam S; Wong WK; Liang R; Ha SY
Haematologica; 2008 Jan; 93(1):116-9. PubMed ID: 18166794
[TBL] [Abstract][Full Text] [Related]
54. Pituitary iron and volume predict hypogonadism in transfusional iron overload.
Noetzli LJ; Panigrahy A; Mittelman SD; Hyderi A; Dongelyan A; Coates TD; Wood JC
Am J Hematol; 2012 Feb; 87(2):167-71. PubMed ID: 22213195
[TBL] [Abstract][Full Text] [Related]
55. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.
Piga A; Gaglioti C; Fogliacco E; Tricta F
Haematologica; 2003 May; 88(5):489-96. PubMed ID: 12745268
[TBL] [Abstract][Full Text] [Related]
56. T2* relaxometry in liver, pancreas, and spleen in a healthy cohort of one hundred twenty-nine subjects-correlation with age, gender, and serum ferritin.
Schwenzer NF; Machann J; Haap MM; Martirosian P; Schraml C; Liebig G; Stefan N; Häring HU; Claussen CD; Fritsche A; Schick F
Invest Radiol; 2008 Dec; 43(12):854-60. PubMed ID: 19002057
[TBL] [Abstract][Full Text] [Related]
57. Combined oral and parenteral iron chelation in beta thalassaemia major.
Balveer K; Pyar K; Wonke B
Med J Malaysia; 2000 Dec; 55(4):493-7. PubMed ID: 11221163
[TBL] [Abstract][Full Text] [Related]
58. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major.
Waheed N; Ali S; Butt MA
J Ayub Med Coll Abbottabad; 2014; 26(3):297-300. PubMed ID: 25671931
[TBL] [Abstract][Full Text] [Related]
59. Pancreatic iron stores assessed by magnetic resonance imaging (MRI) in beta thalassemic patients.
de Assis RA; Ribeiro AA; Kay FU; Rosemberg LA; Nomura CH; Loggetto SR; Araujo AS; Fabron Junior A; de Almeida Veríssimo MP; Baldanzi GR; Espósito BP; Baroni RH; Wood JC; Hamerschlak N
Eur J Radiol; 2012 Jul; 81(7):1465-70. PubMed ID: 21501938
[TBL] [Abstract][Full Text] [Related]
60. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine.
Moayedi B; Gharagozloo M; Esmaeil N; Maracy MR; Hoorfar H; Jalaeikar M
Eur J Haematol; 2013 Mar; 90(3):202-9. PubMed ID: 23278124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]